Format

Send to

Choose Destination
Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Author information

1
University of Nice Sophia Antipolis, Institute for Research on Cancer and Aging of Nice, CNRS UMR 7284, INSERM U1081, 33 av. Valombrose, Centre Antoine Lacassagne, France.
2
Centre Scientifique de Monaco, Biomedical Department, 8 Quai Antoine Ier, Monaco MC-98000, Principality of Monaco.
3
Centre Antoine Lacassagne, Statistic Department, Nice, France.
4
Centre Antoine Lacassagne, Clinical Research Department, Nice, France.
5
University of Bordeaux, INSERM U1029, Pessac, France.
6
Department of Pathology, Nice University Hospital, University of Nice Sophia Antipolis, Nice, France.
7
University of Nice Sophia Antipolis, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France.
8
Institut Gustave Roussy, Villejuif, France.
9
Department of Pathology, University Hospital, Rennes, France.
10
Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
11
Centre Léon Bérard, Lyon, France.

Abstract

BACKGROUND:

Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.

METHODS:

Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS).

RESULTS:

The cut-off value of CXCL7 for PFS was 250 ng ml-1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml-1) had a significantly longer PFS (hazard ratio 0.323 (95% confidence interval 0.147-0.707), P=0.001). These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients.

CONCLUSIONS:

CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients.

PMID:
28850564
PMCID:
PMC5625677
DOI:
10.1038/bjc.2017.276
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center